Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTRACT-2: ASA404 + Docetaxel in NSCLC
NCT00738387Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2008
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing ASA404 + docetaxel with Placebo + docetaxel (2 arms). Primary endpoint: Overall Survival. Started Dec 2008; status: terminated.
02
Drugs
vadimezan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00738387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00738387.